Michael Højby Rasmussen

3.2k total citations
96 papers, 2.4k citations indexed

About

Michael Højby Rasmussen is a scholar working on Endocrinology, Diabetes and Metabolism, Physiology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Michael Højby Rasmussen has authored 96 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Endocrinology, Diabetes and Metabolism, 26 papers in Physiology and 25 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Michael Højby Rasmussen's work include Growth Hormone and Insulin-like Growth Factors (71 papers), Childhood Cancer Survivors' Quality of Life (22 papers) and Diet and metabolism studies (20 papers). Michael Højby Rasmussen is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (71 papers), Childhood Cancer Survivors' Quality of Life (22 papers) and Diet and metabolism studies (20 papers). Michael Højby Rasmussen collaborates with scholars based in Denmark, United States and Japan. Michael Højby Rasmussen's co-authors include J. Hilsted, Anders Juul, Michael Kjær, Jens Sandahl Christiansen, Kai Henrik Wiborg Lange, Leif Breum, A. Hvidberg, Meryl Brod, Lise Kjems and N E Skakkebæk and has published in prestigious journals such as Journal of Applied Physics, American Journal of Clinical Nutrition and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Michael Højby Rasmussen

90 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Højby Rasmussen Denmark 29 1.5k 693 559 337 326 96 2.4k
Jacky M. Burrin United Kingdom 30 992 0.7× 335 0.5× 580 1.0× 76 0.2× 101 0.3× 93 2.6k
Hanna Laine Finland 30 593 0.4× 732 1.1× 422 0.8× 94 0.3× 1.3k 3.9× 73 3.0k
Yoshifumi Sato Japan 25 337 0.2× 941 1.4× 729 1.3× 44 0.1× 177 0.5× 84 2.3k
Thomas B. Price United States 28 629 0.4× 1.9k 2.8× 1.1k 2.0× 61 0.2× 432 1.3× 59 4.2k
Nathan T. Jenkins United States 33 299 0.2× 1.3k 1.9× 657 1.2× 55 0.2× 858 2.6× 103 3.1k
Alex F. Muller Switzerland 25 880 0.6× 269 0.4× 467 0.8× 101 0.3× 133 0.4× 53 2.3k
Pai C. Kao United States 24 549 0.4× 243 0.4× 397 0.7× 64 0.2× 102 0.3× 53 2.0k
Seul‐Ki Jeong South Korea 28 241 0.2× 300 0.4× 494 0.9× 63 0.2× 329 1.0× 116 2.3k
W. V. Tamborlane United States 13 1.0k 0.7× 382 0.6× 216 0.4× 130 0.4× 107 0.3× 22 1.9k

Countries citing papers authored by Michael Højby Rasmussen

Since Specialization
Citations

This map shows the geographic impact of Michael Højby Rasmussen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Højby Rasmussen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Højby Rasmussen more than expected).

Fields of papers citing papers by Michael Højby Rasmussen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Højby Rasmussen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Højby Rasmussen. The network helps show where Michael Højby Rasmussen may publish in the future.

Co-authorship network of co-authors of Michael Højby Rasmussen

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Højby Rasmussen. A scholar is included among the top collaborators of Michael Højby Rasmussen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Højby Rasmussen. Michael Højby Rasmussen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Miller, Bradley S., Joanne Blair, Michael Højby Rasmussen, et al.. (2025). Efficacy, safety, and insulin-like growth factor I of weekly somapacitan in children with growth hormone deficiency: 3-year results from REAL4. European Journal of Endocrinology. 192(5). 651–661. 2 indexed citations
2.
3.
Rasmussen, Michael Højby, John Brodersen, Claus Lohman Brasen, et al.. (2025). The diagnostic accuracy of plasma and serum calprotectin is inferior to C-reactive protein in patients with suspected Crohn’s disease. Scandinavian Journal of Gastroenterology. 60(3). 235–242. 1 indexed citations
4.
5.
Mori, Jun, Yasuhisa Ohata, Yasuko Fujisawa, et al.. (2024). Effective growth hormone replacement with once‐weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial. Clinical Endocrinology. 100(4). 389–398. 6 indexed citations
6.
Sävendahl, Lars, Tadej Battelino, Michael Højby Rasmussen, et al.. (2023). Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment/Disease Burden Results From REAL 3. The Journal of Clinical Endocrinology & Metabolism. 108(10). 2569–2578. 21 indexed citations
7.
Miller, Bradley S., Joanne Blair, Michael Højby Rasmussen, et al.. (2022). Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial. The Journal of Clinical Endocrinology & Metabolism. 107(12). 3378–3388. 33 indexed citations
8.
Miller, Bradley S., Joanne Blair, Michael Højby Rasmussen, et al.. (2022). RF14 | LBMON195 Once-weekly Somapacitan Is Effective And Well Tolerated In Children With GH Deficiency: A Randomized Phase 3 Trial. Journal of the Endocrine Society. 6(Supplement_1). A640–A641. 1 indexed citations
9.
Sävendahl, Lars, Tadej Battelino, Michael Højby Rasmussen, Reiko Horikawa, & Paul Saenger. (2021). Once-Weekly Somapacitan Versus Daily Growth Hormone in Growth Hormone Deficiency: 2-Year Efficacy Results From REAL 3, a Randomized Phase 2 Trial. Journal of the Endocrine Society. 5(Supplement_1). A680–A680.
10.
Brod, Meryl, et al.. (2019). Growth Hormone Deficiency (GHD): Assessing Parent Burden for Child Growth Hormone Deficiency Treatment: The Growth Hormone Deficiency - Parent Treatment Burden Measure (GHD-PTB). 92. 1 indexed citations
11.
Brod, Meryl, et al.. (2017). Understanding Treatment Burden for Children Treated for Growth Hormone Deficiency. Patient. 10(5). 653–666. 38 indexed citations
12.
Brod, Meryl, et al.. (2016). Assessing Disease and Treatment Burden for Young Children with Growth Hormone Deficiency (GHD). 86. 1 indexed citations
13.
Rasmussen, Michael Højby, Marianne Klose, Mette Tanvig, et al.. (2016). Reversible Albumin-Binding GH Possesses a Potential Once-Weekly Treatment Profile in Adult Growth Hormone Deficiency. The Journal of Clinical Endocrinology & Metabolism. 101(3). 988–998. 26 indexed citations
14.
Zuckerman‐Levin, Nehama, et al.. (2015). A Novel Reversible Albumin-Binding GH Derivative Possesses a Promising Once-Weekly Treatment Profile in Children with GH Deficiency. 84.
15.
Rasmussen, Michael Højby, Marianne Klose, Mette Tanvig, et al.. (2014). S.c. Injections of a Reversible Albumin-Binding GH Derivative (NNC0195-0092) in Adult Subjects with GH Deficiency is Well Tolerated. 82.
16.
Hannallah, Medhat, et al.. (2013). Evaluation of dexmedetomidine/propofol anesthesia during upper gastrointestinal endoscopy in patients with high probability of having obstructive sleep apnea. 17(3). 257–260. 3 indexed citations
17.
Raschke, Mi cha el J., et al.. (2007). Effects of growth hormone in patients with tibial fracture: a randomised, double-blind, placebo-controlled clinical trial. European Journal of Endocrinology. 156(3). 341–351. 37 indexed citations
18.
Rasmussen, Michael Højby, Anders Juul, Lise Kjems, & J. Hilsted. (2006). Effects of short-term caloric restriction on circulating free IGF-I, acid-labile subunit, IGF-binding proteins (IGFBPs)-1–4, and IGFBPs-1–3 protease activity in obese subjects. European Journal of Endocrinology. 155(4). 575–581. 30 indexed citations
19.
Rasmussen, Michael Højby, Ken K. Y. Ho, Lise Kjems, & J. Hilsted. (1996). Serum growth hormone-binding protein in obesity: effect of a short-term, very low calorie diet and diet-induced weight loss.. The Journal of Clinical Endocrinology & Metabolism. 81(4). 1519–1524. 47 indexed citations
20.
Hilsted, J., Sten Madsbad, A. Hvidberg, et al.. (1995). Intranasal insulin therapy: the clinical realities. Diabetologia. 38(6). 680–684. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jacky M. Burrin Breakdown of academic impact, for papers by Hanna Laine Breakdown of academic impact, for papers by Yoshifumi Sato Breakdown of academic impact, for papers by Thomas B. Price Breakdown of academic impact, for papers by Nathan T. Jenkins Breakdown of academic impact, for papers by Alex F. Muller Breakdown of academic impact, for papers by Pai C. Kao Breakdown of academic impact, for papers by Seul‐Ki Jeong Breakdown of academic impact, for papers by W. V. Tamborlane
Rankless by CCL
2026